Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955521 | 0.80 | HRH3 (0.69) | HRH3KCNH2 | |
| SCHEMBL2560110 | 0.80 | SIGMAR1 (0.45) | LTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL25997216 | 0.78 | HRH3 (0.68) | HRH3LTA4HALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL4719530 | 0.78 | HRH3 (0.68) | HRH3LTA4HALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL13218336 | 0.78 | HRH3 (0.68) | HRH3LTA4HALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL1862838 | 0.77 | HRH3 (1.00) | HRH3LTA4H | |
| SCHEMBL26003876 | 0.77 | HRH3 (0.65) | HRH3LTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL17272511 | 0.77 | HRH3 (0.65) | HRH3LTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL25493131 | 0.76 | HRH3 (0.60) | HRH3LTA4HALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL9906445 | 0.75 | HRH3 (0.66) | HRH3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954828-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-116322699-B | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4219499-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219499-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-116322699-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | ATM, CHEK2, CHEK1 | HRH3 2978/4885LTA4H 4448/4885ALDH1A1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.